Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corvus Pharmaceuticals, Inc. - Common Stock (NQ:CRVS)

10.35 -0.17 (-1.62%)
Delayed Quote Updated: 10:07 AM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Corvus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript ↗
Soquelitinib advances across multiple indications, with cash runway extended into 2028. 
Via The Motley Fool
Topics Earnings
News headline image
Corvus Pharmaceuticals Q2 Earnings Call Highlights ↗
Corvus Pharmaceuticals (NASDAQ:CRVS) reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected... 
Via MarketBeat
Topics Earnings
Corvus Pharmaceuticals (NASDAQ:CRVS) Misses Q2 Loss Estimates as Clinical-Stage Spending Continues ↗
Via Chartmill
News headline image
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy? ↗
Immuno-oncology specialist Corvus Pharmaceuticals reported a recent insider buy amid a year of sharp share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
Corvus Pharmaceuticals Reports Q1 2026 Results; Atopic Dermatitis Program Takes Center Stage (NASDAQ:CRVS) ↗
Via Chartmill
Corvus Pharmaceuticals (NASDAQ:CRVS) Reports Q4 Earnings Miss Amid Positive Pipeline Data ↗
Via Chartmill
Topics Earnings
Why Is CRVS Stock Rising Today? ↗
Via Stocktwits
News headline image
Adams Street Partners Exits Its 223,000-Share Paymentus (PAY) Position for $5.9 Million ↗
This cloud-based payments provider delivers SaaS solutions to enterprise billers across utilities, finance, and healthcare sectors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗
Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Corvus (CRVS) Q4 2025 Earnings Call Transcript ↗
Corvus (CRVS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 ↗
Via MarketBeat
News headline image
CRVS Stock Surges Pre-Market After Corvus Expands Equity Raise To $175 Million ↗
Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock available for purchase at Wednesday’s closing price of $22.15. 
Via Stocktwits
Dow, Nasdaq, S&P 500 Futures Tick Higher After Wall Street’s Worst Day In 3 Months: Why NFLX, AAPL, CRVS, GME, UAL Are In Focus Today ↗
Via Stocktwits
Topics Stocks
News headline image
Corvus Pharma Stock Dips Over 6% After-Hours Following Best Day Ever — What Went Wrong? ↗
The update follows the company’s release of cohort 4 data from its atopic dermatitis study of Soquelitinib. 
Via Stocktwits
News headline image
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data ↗
Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, 2026. 
Via The Motley Fool
Topics Stocks
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Tuesday's session: top gainers and losers ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise on Clinical Progress ↗
Corvus Pharmaceuticals reported a narrower Q2 2025 loss of $0.10 per share, beating estimates, with shares rising 5.8% after-hours. Positive Phase 1 data for soquelitinib in atopic dermatitis boosted... 
Via Chartmill
News headline image
Corvus (CRVS) Q2 Loss Beats Estimates ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased ↗
Corvus announced new interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis. 
Via Stocktwits
News headline image
Why Is Corvus Pharmaceuticals Stock Soaring On Friday? ↗
Corvus Pharmaceuticals, Inc.(NASDAQ:CRVS) on Thursday released new interim data from the Phase 1 clinical trial evaluating ... 
Via Benzinga
News headline image
Wondering what's happening in today's pre-market session? ↗
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.